Stocks To Buy Now

Blog

The Stocks To Buy Now Blog

Our team has been covering the micro- and small-cap markets for more than a decade, exploring a wide variety of trends, technology and news in every industry. The Stocks to Buy Now blog seeks out undervalued companies, covers their news, breaks down the jargon, and delivers accurate and timely information to you on a daily basis.

If you’re looking for market insight, undervalued gems, and an assortment of investment options, read on.

Legacy Ventures International, Inc. (LGYV) Announces Agreement to Supply Boxed Water to Major Retailer in Canada

Legacy Ventures International, Inc. (OTC: LGYV) recently announced that its wholly-owned subsidiary, RM Fresh Brands, has entered into an agreement with CJR Wholesale Grocers Ltd to supply Boxed Water to Rabba Fine Foods. Since 1967, Toronto-based Rabba Fine Foods has become an influential name in the Canadian retail industry by offering a quality selection of […]

Nutra Pharma Corp. (NPHC) Applies for Additional Orphan Drug Designation for RPI-78M

Nutra Pharma Corp., a biotechnology company marketing Nyloxin® and Pet Pain-Away in the over-the-counter (OTC) pain management market, as well as developing treatments for multiple sclerosis (MS), human immunodeficiency virus (HIV), adrenomyeloneuropathy (AMN) and pain, announced today that it has applied for an Orphan Drug designation from the U.S.-FDA for the Company’s RPI-78M drug candidate […]

International Stem Cell Corp. (ISCO) Has a Broad Pipeline of Targets

International Stem Cell Corp. is tackling some of the world’s most debilitating health maladies with a powerful new stem cell technology that employs parthenogenesis. Parthenogenesis is a type of reproduction that takes place in the absence of fertilization. The company’s new stem cell technology holds the promise of advancing significantly the field of regenerative medicine […]

 

From Our Blog

Soligenix Inc. (NASDAQ: SNGX) Builds Momentum in Fight Against Rare, Chronic Cancer

February 2, 2026

Cutaneous T-cell lymphoma (“CTCL”) remains a cancer with limited treatment options, persistent symptoms and long-term quality-of-life challenges for patients, even decades after its classification as a distinct disease. Despite medical advances in oncology, many people living with CTCL continue to cycle through therapies that offer only partial relief or introduce new burdens. Soligenix (NASDAQ: SNGX) […]

Rotate your device 90° to view site.